Frecuencia de mutaciones del gen ABL en pacientes con leucemia mieloide crónica resistentes a imatinib y resultado del cambio de tratamiento a inhibidores de tirosín-cinasa de segunda generación

Marcé, Silvia; Zamora, Lurdes; Cabezón, Marta; Xicoy, Blanca; Boqué, Concha; Fernández, Cristalina; Grau, Javier; Navarro, José Tomás; Fernández de Sevilla, Alberto; Ribera, Josep María; Feliu, Evarist; Millá, Fuensata.
Med. clín (Ed. impr.) ; 141(3): 95-99, ago. 2013.
Artículo en Inglés | IBECS (España) | ID: ibc-114376

Documentos relacionados

  1. [State-of-the-art management of CML in 2015 and future prospects].
  2. Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report.
  3. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
  4. [Chronic myeloid leukemia: update on treatment and survival prediction].
  5. Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia.
  6. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
  7. Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance.
  8. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
  9. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
  10. [Evolvement of a five-way translocation t(5;9;22;6;17) from a four-way Philadelphia translocation t(5;9;22;6) in a rare case of chronic myeloid leukemia].